PSTV (Plus Therapeutics) Total Operating Expense: $18.88 Mil (TTM As of Mar. 2026)


PSTV Plus Therapeutics Inc PSTV
26 GF Score
Price $4.30
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Total Operating Expense?

Plus Therapeutics PSTV +1.65% 26 Total Operating Expense is $18.88 Mil as of Mar. 2026. GuruFocus rates PSTV with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Plus Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $7.12 Mil. Plus Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $18.88 Mil.

Plus Therapeutics Total Operating Expense Related Terms

Plus Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Plus Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Plus Therapeutics Total Operating Expense Chart

Plus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.43 19.71 13.32 14.70 15.30

Plus Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.54 1.54 4.48 5.74 7.12
PSTV
26GF Score
Plus Therapeutics Inc PSTV
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Plus Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $18.88 Mil mean?
Plus Therapeutics (PSTV) has a Total Operating Expense of $18.88 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Plus Therapeutics and its competitors.
Is Plus Therapeutics' Total Operating Expense too high?
Plus Therapeutics' current Total Operating Expense is $18.88 Mil. Overall, Plus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Total Operating Expense compare to KYNB and VTGN?
Plus Therapeutics' Total Operating Expense of $18.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Plus Therapeutics and its competitors. Plus Therapeutics's current Total Operating Expense is $18.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Total Operating Expense of $18.88 Mil. The current Total Operating Expense is $18.88 Mil. Plus Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Total Operating Expense is $18.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
26GF Score

Get the complete analysis for PSTV

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price